News
Release date:2020/7/28 5:58:18

So far, small molecules and macromolecules, including antibodies, have become the most pursued substances in drug screening and development efforts. Although they have many advantageous characteristics as drugs, these molecules still have limitations and are not complementary in many regards. Recently, peptide-based chemical structures that lie between these two categories in terms of both structural and functional properties have gained increasing attention as potential alternatives. In particular, cyclic peptides provide a promising scaffold for the development of a novel drug class owing to their adjustable and expandable ability to bind a wide range of target molecules.

Cyclic peptides are polypeptide chains taking cyclic ring structures, which plays a very important role in natural products. Cyclic peptides are a class of peptide molecules with stable and uniform conformation. They have a high selective affinity for receptors, strong metabolic stability, and high oral availability. As a drug molecule, cyclic peptide has a wide range of biological activities such as anticancer, antiviral, antibacterial, antifungal, and enzyme inhibition. In recent years, as the discovery and synthesis technology of cyclic peptide molecules has become more and more mature, the drug development of such molecules has also attracted more and more attention, and certain progress has been made. 

Depending on the cyclization site, there are nine general methods to synthesize cyclic peptides, e.g. head-to-tail cyclization, side-chain-to-side-chain, head-to-side-chain, and side-chain-to-tail cyclization (see figure below). Among the mentioned ones, the two latter methods are the most frequently utilized. While head-to-tail cycles are usually formed by amide bond formation, side-chain-to-side-chain cycles are most often synthesized via Cys-Cys or amide bond formation within a cyclic peptide.

Peptide cyclization
Image: nine general methods to synthesize cyclic peptides, source: https://www.jpt.com/

Cyclic peptides have achieved great success in drug therapy. Common cyclic peptides include hormones and hormone analogues Oxytocin, Octreotide and Vasopressin; antibiotics such as Vancomycin, Daptomycin, and Polymyxin B; immunosuppressant Cyclosporine, etc. So far, there are more than 40 kinds of cyclic peptide drugs in clinical applications. On average, about one cyclic peptide drugs enter the therapeutic market every year. The reason why cyclic peptides show their talents in the field of drug research and development is related to several characteristics.

  • ▶ First of all, due to the restriction of conformational changes caused by the cyclic structure, cyclic peptides generally have a large surface area, so that they have a high affinity and recognition specificity with the target protein. The limitation of conformational flexibility of the macrocyclic structure also reduces the entropy value of the binding of the drug to the target and improves the stability of the binding.
  • ▶ Secondly, the characteristics of amino acid composition confirm that cyclic peptides tend to have extremely low or even no cytotoxicity.
  • ▶ Third, cyclic peptides are easily produced through automated chemical synthesis processes and are convenient for various modifying, processing and monitoring. These features are very conducive to the drug development process.

Cyclic Peptide Drugs Approved In 2006-2015

In 2006-2015, the FDA and EMA have approved nine cyclic peptide drugs, which account for only 3% of the new drugs that entered the market in this time period. Four of these cyclic peptides, telavancin, dalbavancin, oritavancin, and anidulafungin, are employed in bacterial and fungal infections. Three peptides, lanreotide, romidepsin, and pasireotide are oncology drugs, and one, linaclotide, is specific for gastrointestinal disorders. The last drug, peginesatide, was approved by the U.S. FDA on March 27, 2012 for the treatment of anemia during dialysis. Structurally, the drug achieves dimerization through PEG molecules, thereby increasing its affinity with proteins and the half-life in the blood. Regrettably, it was withdrawn one year after approval due to safety concerns. Unlike all other drugs mentioned above, Peginesatide is the first cyclic peptide drug to adopt a de novo strategy.

Table 1 FDA and EMA Approved Cyclic Peptide Drugs in 2006-2015
Name Approved Time Indication Mechanism of Action Company
Anidulafungin 2006 fungal infections fungal 1,3-ß-Dglucan synthase inhibitor Vicuron/Pfizer
Lanreotide 2007 neuroendocrine tumors, acromegaly growth hormone
release inhibitor
Ipsen
Telavancin 2009 complicated skin and skin structure infections (cSSSI)/hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP) bacterial cell-wall
synthesis inhibitor
Theravance
Romidepsin 2009 cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL) Histone deacetylase inhibitors Gloucester Pharmaceuticals/Celgene
Peginesatide 2012 anemia due to chronic kidney disease (CKD)  erythropoiesis
stimulating agent
 Affymax/Takeda
Linaclotide 2012 irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation guanylate cyclase
2C receptor
activator
Forest Labs/Ironwood Pharmaceuticals
Pasireotide 2012 Cushing’s disease, acromegaly,  neuroendocrine tumors growth hormone
release inhibitor
Novartis
Dalbavancin 2014 acute bacterial skin and skin structure infections (ABSSSI) bacterial cell-wall
synthesis inhibitor
Durata Therapeutics/Teva
Oritavancin 2014 acute bacterial skin and skin structure (including subcutaneous) infection bacterial cell-wall
synthesis inhibitor
The Medicines Company

Table 1. Cyclic peptide drugs approved in 2006-2015 by the FDA and/or EMA. 

Among the 9 approved cyclic peptide drugs mentioned above, eight have similar mechanisms of action to established drugs and only one, linaclotide, is a first-in-class drug. In addition to being highly innovative and applicable to large patients, Linaclotide is also eye-catching in terms of sales. It generated revenues of 460 million USD, improving upon the already impressive sales of 140 and 300 million USD in the two first years after approval. Lanreotide and Romidepsin are two other drugs that perform equally well, with sales reaching 440 million and 70 million US dollars in 2015, respectively.

FDA and EMA Approved Cyclic Peptide Drugs in 2006-2015
Image: Cyclic peptide drugs approved in 2006-2015 by the FDA and/or EMA. Source: https://pubmed.ncbi.nlm.nih.gov/28249193/

Cyclic Peptides In Clinical Development

There are several cyclic peptides currently in clinical development for a variety of indications as highlighted in Table 2 below.

Table 2 Selection of Cyclic Peptides in Phase I to Phase III Clinical Development
Product Name Generic Name Indication Highest Phase Company
Vyleesi bremelanotide Erectile Dysfunction, Female Sexual Dysfunction, Female Hypoactive Sexual Desire Disorder Pre-registration Palatin Technologies Inc
APL-2 pegcetacoplan Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy, Autoimmune Hemolytic Anemia, Complement-dependent nephropathies III Apellis Pharmaceuticals Inc
AZP-531 livoletide Obesity, Type 2 Diabetes, Ischemia, Prader-Willi Syndrome (PWS) III Millendo Therapeutics Inc
POL7080 murepavadin Cystic Fibrosis, Bronchiectasis, Ventilator Associated Pneumonia (VAP), Hospital-Acquired Pneumonia (HAP), Pseudomonas Infections III Polyphor AG
BMN 111 vosoritide Achondroplasia III BioMarin Pharmaceutical Inc
ALRN-6924 -- Retinoblastoma, Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) II Aileron Therapeutics Inc
BT-1718 -- Breast Cancer, Sarcomas, Solid Tumor, Squamous Non-Small Cell Lung Cancer II Bicycle Therapeutics Ltd
RA-101495 zilucoplan Lupus Nephritis, Myasthenia Gravis, Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome II Ra Pharmaceuticals Inc
CEND-1 -- Breast Cancer, Ovarian Cancer, Prostate Cancer, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer II DrugCendR Inc
NP-213 novexatin Onychomycosis (Tinea Unguium) II Novabiotics Ltd
POL6014 -- Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Bronchiectasis, Pulmonary Arterial Hypertension, Acute Lung Injury II Santhera Pharmaceuticals Holding AG
POL6326 balixafortide Myocardial Infarction, Asthma, Hematopoietic Stem Cell Transplantation, Inflammation, Metastatic Breast Cancer I Polyphor AG
ShK-186 dalazatide Multiple Sclerosis, Inflammatory Bowel Disease, Lupus Nephritis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Psoriatic Arthritis I Kv1.3 Therapeutics
THR-149 -- Diabetic Macular Edema I Oxurion NV

Table 2 Selection of Cyclic Peptides in Phase I to Phase III Clinical Development

Pre-registration

VyleesiTM (bremelanotide) is a cyclic peptide derivative being developed by Palatin Technologies for female sexual arousal disorder (FSAD). Vyleesi is a synthetic analog of the naturally occurring hormone α-Melanocyte-Stimulating Hormone (α-MSH) which targets the melanocortin 4 receptor. In 2018, Palatin’s North American licensee for bremelanotide, AMAG Pharmaceuticals, submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women.

Phase III Clinical Candidates

Apellis Pharmaceuticals is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria, geographic atrophy, autoimmune hemolytic anemia and other indications. APL-2 is a cyclic peptide conjugated with polyethylene glycol (PEG) polymer that can target complement factor C3 (a protein of the immune system). In 2019, the FDA granted APL-2 fast track designation for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Millendo Therapeutics is developing AZP-531 (livoletide), a cyclic peptide analog of unacylated ghrelin, for the treatment of Prader Willi syndrome and ischemia-related diseases. AZP-531 acts as a growth hormone secretagogue receptor type 1 agonist. In 2019, Millendo Therapeutics initiated a pivotal Phase IIb/III clinical study to investigate livoletide in patients with Praderwilli syndrome.

Polyphor is developing POL7080 (murepavadin), a new type of antibiotic used to treat ventilator-associated pneumonia and hospital-acquired pneumonia caused by Pseudomonas aeruginosa. Murepavadin is a 14-mer cyclic peptide that targets the outer membrane protein of Pseudomonas aeruginosa. In 2019, Polyphor announced that its first patient had participated in a phase III clinical trial of murepavadin, which is used to treat ventilator-associated bacterial pneumonia caused by Pseudomonas aeruginosa. 

BioMarin Pharmaceuticals is developing BMN 111 (vosoritide) for the treatment of achondroplasia (the most common form of dwarfism). Vosoritide is an analog of a small cyclic peptide called C-type natriuretic peptide (CNP), which is a positive regulator of bone growth. The analog peptide is an atrial natriuretic peptide receptor 2 agonist. BioMarin expects that by the end of 2019, their current phase III study of vosoritide in children will have the top-line results.

Future challenges and potential solutions

For the application of cyclic peptide drugs, there are still many challenges, the two most important of which are oral availability and cell permeability. The introduction of some innovative research strategies in recent years has partially solved the above-mentioned challenges, including including the application of cell penetrating peptides, the stabilization of peptides in -helical conformations with nhydrocarbon linkers, or the in vitro evolution of N-methylated peptides. In order to develop cyclic peptide drugs that have good oral availability and can efficiently enter cells through passive diffusion, it is necessary to consider selecting molecules with smaller molecular weight and fewer peptide bonds as candidates. It is foreseeable that the combination of in vitro evolution technology and de novo design strategy with random peptide library screening will surely produce more and more new cyclic peptide drugs.

For researchers and companies engaged in the research and development of cyclic peptides, Biochempeg offers a comprehensive Custom Synthesis Service of PEG Derivatives for the use of cyclic peptides.

References:
1. Selection-based discovery of druglike macrocyclic peptides. Annu Rev Biochem. 2014;83:727-52. doi: 10.1146/annurev-biochem-060713-035456
2. Cyclic peptide therapeutics: past,present and future.Curr Opin Chem Biol. 2017 Jun;38:24-29. doi:.1016/j.cbpa.2017.02.006.
3. Cell-penetrating peptides: 20 years later,where do we stand?FEBS Lett. 2013 Jun 19;587 (12):1693-702. doi:10.1016/j.febslet.2013.04.031.
4. The Future of Peptide-based Drugs. Chem Biol Drug Des 2013; 81: 136–147
5. The Emergence of Cyclic Peptides: The Potential of Bioengineered Peptide Drugs.International Journal of Peptide Research and Therapeutics  Volume 20, Issue 4,pp 545–551
6. Cyclic Peptides as Therapeutic Agents and Biochemical Tools. Biomol Ther (Seoul). 2012Jan;20 (1): 19–26. doi:10.4062/biomolther.2012.20.1.019
7. https://www.jpt.com/products/cyclic-peptides

Previous:Nano Drugs: Let The Blood-Brain Barrier No Longer Be A "Barrier" Next:Liposomes and Lipid Nanoparticles as Pharmaceutical Drug Carriers